Literature DB >> 21732070

Progression of the lung cancer primary correlates with the identification of new brain metastases after initial radiosurgery.

Jung Ho Han1, Dong Gyu Kim, Chang Wan Oh, Chae-Yong Kim, Young Hoon Kim, Jeong Hoon Park, Eun Kyung Kim, Hee-Won Jung.   

Abstract

We retrospectively evaluated the relationship between the response of lung lesions and distant progression-free survival (DPFS) after radiosurgery in patients with brain metastases. A total of 47 consecutive patients were treated with radiosurgery for brain metastases. Distant progression was defined as a new enhancing intracranial tumor or leptomeningeal enhancement noted on follow-up magnetic resonance imaging. Progression of lung lesions was defined as follows: (1) a 20% increase in the summed diameter of the target lesions; (2) an absolute increase of 5 mm when the summed diameter was very small; or (3) detection of new lesions in the lung. Distant progression after radiosurgery was observed for twenty-one (44.7%) patients; we observed development of new distant metastases in nine patients, development of leptomeningeal seeding in eight patients, and combined failure of distant progression and local control failure in four patients. Forty-two (89.4%) patients had lung lesions at the time of radiosurgery, and progression of their lung lesions during the post-radiosurgery follow-up period was observed for 18 (38.3%) of these. The median DPFS was 7.00 months (95% CI, 6.153-7.847). Actuarial DPFS 3, 6, and 12 months after radiosurgery was 81.5, 61.3, and 36.7%, respectively. In multivariate analysis, only the criterion progression of lung lesions reached statistical and independent significance (P = 0.021, OR = 3.372, 95% CI, 1.200-9.480). The response of lung lesions after radiosurgery is likely to be a good predictor of DPFS after radiosurgery in patients with brain metastases.

Entities:  

Mesh:

Year:  2011        PMID: 21732070     DOI: 10.1007/s11060-011-0653-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.

Authors:  Hidefumi Aoyama; Masao Tago; Norio Kato; Tatsuya Toyoda; Masahiro Kenjyo; Saeko Hirota; Hiroki Shioura; Taisuke Inomata; Etsuo Kunieda; Kazushige Hayakawa; Keiichi Nakagawa; Gen Kobashi; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-01       Impact factor: 7.038

3.  A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.

Authors:  Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-10       Impact factor: 7.038

4.  Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.

Authors:  E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-05-01       Impact factor: 7.038

5.  Gamma knife surgery in the management of brain metastases from lung carcinoma: a retrospective analysis of survival, local tumor control, and freedom from new brain metastasis.

Authors:  Ajay Jawahar; Ronnie E Matthew; Alireza Minagar; Deepti Shukla; John H Zhang; Brian K Willis; Federico Ampil; Anil Nanda
Journal:  J Neurosurg       Date:  2004-05       Impact factor: 5.115

Review 6.  Brain metastases.

Authors:  Andrew B Lassman; Lisa M DeAngelis
Journal:  Neurol Clin       Date:  2003-02       Impact factor: 3.806

7.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Authors:  David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

8.  Prophylactic cranial irradiation in extensive small-cell lung cancer.

Authors:  Ben Slotman; Corinne Faivre-Finn; Gijs Kramer; Elaine Rankin; Michael Snee; Matthew Hatton; Pieter Postmus; Laurence Collette; Elena Musat; Suresh Senan
Journal:  N Engl J Med       Date:  2007-08-16       Impact factor: 91.245

9.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

10.  Thirty years' experience with Gamma Knife surgery for metastases to the brain.

Authors:  Bengt Karlsson; Patrick Hanssens; Robert Wolff; Michael Söderman; Christer Lindquist; Guus Beute
Journal:  J Neurosurg       Date:  2009-09       Impact factor: 5.115

View more
  2 in total

1.  Stereotactic radiosurgery for brain metastases from hepatocellular carcinoma.

Authors:  Jung Ho Han; Dong Gyu Kim; Hyun-Tai Chung; Sun Ha Paek; Chul-Kee Park; Chae-Yong Kim; Young-Hoon Kim; Hee-Won Jung
Journal:  J Neurooncol       Date:  2013-06-29       Impact factor: 4.130

2.  Gamma knife surgery for brain metastasis from hepatocellular carcinoma.

Authors:  Qingsheng Xu; Pan Wu; Yiping Feng; Ke Ye; Ying Tong; Yongqing Zhou
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.